Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect.

摘要: Abstract Background To ensure identification of anaplastic lymphoma kinase-positive (ALK+) patients, the Italian Drug Agency suggested a testing algorithm based on use fluorescence in situ hybridization (FISH) and/or immunohistochemistry. The aim was to evaluate clinical and economic effects adopting an immunohistochemical test (Ventana ALK D5F3) as option for detecting protein expression advanced non–small cell lung cancer (NSCLC) patients. Materials Methods A budget impact model developed by National Health Service (NHS) perspective 5-year period compare 2 scenarios: current D5F3 (28%; scenario) increased (60%; alternative scenario). cost number identified ALK+ patients were evaluated. Results more extensive scenario showed decrease diagnostic costs ∼€468,000 compared with when considering all NSCLC If these savings allocated (75% vs. 53%), incremental per patient €63 would be required, leading overall survival gain (32.4 27.1 months; relative increase, 20%). Conclusion provide NHS owing lower acquisition than FISH comparable detection rate. could reinvested greater efficient identification, targeted therapy, improvement outcomes